Azura Ophthalmics is taking a unique approach to the treatment of ocular surface disease (OSD).
Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as Meibomian gland dysfunction (MGD), Blepharitis and Contact Lens Discomfort.
Because Meibomian glands in the eyelids are similar to the hair fol...
Azura Ophthalmics is taking a unique approach to the treatment of ocular surface disease (OSD).
Azura Ophthalmics is taking a unique pharmaceutical approach to ocular surface disease: we are developing the first ophthalmic keratolytics for the treatment of lid margin diseases such as Meibomian gland dysfunction (MGD), Blepharitis and Contact Lens Discomfort.
Because Meibomian glands in the eyelids are similar to the hair follicles and sebaceous (oil-producing) glands of the skin1, our approach combines ophthalmologic and dermatologic strategies to develop effective treatments for MGD and related conditions.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.